Extramedullary immunoprivileged sites as a niche for residual and relapsed
FLT3-
ITD mutated AML: an unmet clinical need
Leuk Lymphoma
.
2024 Nov 28:1-5.
doi: 10.1080/10428194.2024.2431880.
Online ahead of print.
Authors
Philip D Tracy
1
2
,
Ruben Delgado
3
,
Ahmad Al-Akdi
3
,
Monika Pilichowska
3
,
Zheng Zhou
1
2
Affiliations
1
Division of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA.
2
Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
3
Department of Pathology, Tufts Medical Center, Boston, MA, USA.
PMID:
39607871
DOI:
10.1080/10428194.2024.2431880
No abstract available